| pubmed-article:18076807 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18076807 | lifeskim:mentions | umls-concept:C0346647 | lld:lifeskim |
| pubmed-article:18076807 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:18076807 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:18076807 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:18076807 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:18076807 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:18076807 | pubmed:dateCreated | 2007-12-13 | lld:pubmed |
| pubmed-article:18076807 | pubmed:abstractText | Gemcitabine (GEM) is efficient in treating advanced pancreatic cancer. Preliminary clinical studies showed that the efficacy of gemcitabine combined oxaliplatin (GEMOX regimen) is better than that of gemcitabine alone. But in China, the use of GEMOX regimen for advance pancreatic cancer has seldom been reported. This study was to analyze the efficacy of GEMOX regimen on advanced pancreatic cancer, and observe the adverse events. | lld:pubmed |
| pubmed-article:18076807 | pubmed:language | chi | lld:pubmed |
| pubmed-article:18076807 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076807 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18076807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18076807 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18076807 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:18076807 | pubmed:issn | 1000-467X | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:ZhangLiL | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:HanBingB | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:WangFengF | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:GuanZhong-Zhe... | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:JiangWen-QiWQ | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:XiaZhong-JunZ... | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:LiYu-HongYH | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:XuRui-HuaRH | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:HeYou-JianYJ | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:LinTong-YuTY | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:ShiYan-XiaYX | lld:pubmed |
| pubmed-article:18076807 | pubmed:author | pubmed-author:LuoHui-YanHY | lld:pubmed |
| pubmed-article:18076807 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18076807 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:18076807 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18076807 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18076807 | pubmed:pagination | 1381-4 | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:meshHeading | pubmed-meshheading:18076807... | lld:pubmed |
| pubmed-article:18076807 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:18076807 | pubmed:articleTitle | [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer]. | lld:pubmed |
| pubmed-article:18076807 | pubmed:affiliation | State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China. | lld:pubmed |
| pubmed-article:18076807 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18076807 | pubmed:publicationType | English Abstract | lld:pubmed |
